Sight Sciences (Sight Sciences) EV-to-Revenue : 2.33 (As of May. 22, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sight Sciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sight Sciences's enterprise value is $189.84 Mil. Sight Sciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $81.50 Mil. Therefore, Sight Sciences's EV-to-Revenue for today is 2.33.

The historical rank and industry rank for Sight Sciences's EV-to-Revenue or its related term are showing as below:

SGHT' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.44 Med: 4.01 Max: 41.51
Current: 2.33

During the past 6 years, the highest EV-to-Revenue of Sight Sciences was 41.51. The lowest was -0.44. And the median was 4.01.

SGHT's EV-to-Revenue is ranked better than
60.84% of 830 companies
in the Medical Devices & Instruments industry
Industry Median: 3.265 vs SGHT: 2.33

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-22), Sight Sciences's stock price is $5.46. Sight Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.67. Therefore, Sight Sciences's PS Ratio for today is 3.28.

Sight Sciences EV-to-Revenue Historical Data

The historical data trend for Sight Sciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sight Sciences EV-to-Revenue Chart

Sight Sciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

12.42

6.16

1.86

Sight Sciences Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial														3.87	3.47	0.66	1.86	2.08

Competitive Comparison of Sight Sciences's EV-to-Revenue

For the Medical Devices subindustry, Sight Sciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sight Sciences's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sight Sciences's EV-to-Revenue falls into.

Sight Sciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Sight Sciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	189.842	/	81.496
	=	2.33

Sight Sciences's current Enterprise Value is $189.84 Mil.
Sight Sciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $81.50 Mil.

Sight Sciences (NAS:SGHT) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Sight Sciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	5.46	/	1.667
	=	3.28

Sight Sciences's share price for today is $5.46.
Sight Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.67.

Sight Sciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sight Sciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sight Sciences (Sight Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sight Sciences Inc (NAS:SGHT) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.sightsciences.com

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Executives

Jeremy B. Hayden	officer: Chief Legal Officer	2 MUSICK, 2 MUSICK, IRVINE CA 92618
Sam Boong Park	officer: Chief Operating Officer	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Paul Badawi	director, 10 percent owner, officer: President and CEO	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
David Badawi	director, officer: Chief Technology Officer	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
D1 Capital Partners L.p.	10 percent owner	9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Staffan Encrantz	director	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Matthew Link	officer: Chief Commercial Officer	7475 LUSK BLVD, SAN DIEGO CA 92121
Catherine Mazzacco	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Alison Bauerlein	officer: See remarks	326 BOLLAY DRIVE, GOLETA CA 93117
James Rodberg	officer: See Remarks	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVE., SUITE 100, MENLO PARK CA 94025
Tamara Fountain	director	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Brenda Jane Larsen-becker	director	C/O SIGHT SCIENCES, INC., 3000 SAND HILL ROAD, BUILDING 3, STE 105, MENLO PARK CA 94025
Jesse Selnick	officer: Chief Financial Officer	C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Daniel S. Sundheim	10 percent owner	C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Erica J. Rogers	director	C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089